Phosphodiesterase4 inhibitors are currently under development for the treatment of
respiratory diseases including asthma and chronic obstructive pulmonary disease. The …

Phosphodiesterases (PDE) belong to an important family of proteins that regulate the
intracellular levels of cyclic nucleotide second messengers. Targeting PDE with selective …

PDE4 inhibitors can suppress a variety of inflammatory cell functions that contribute to their
anti-inflammatory actions in respiratory diseases like chronic obstructive pulmonary disease …

Since the early 1980s, phosphodiesterase 4 (PDE4) has been an attractive target for the
treatment of inflammation-based diseases. Several scientific advancements, by both …

Phosphodiesterase 4 (PDE4) is a major cyclic adenosine-3′, 5′-monophosphate-
metabolizing enzyme in immune and inflammatory cells, airway smooth muscle, and …

Phosphodiesterase 4 (PDE4) is a major cyclic AMP-hydrolyzing enzyme in inflammatory and
immunomodulatory cells. The wide range of inflammatory mechanisms under control by …

Asthma and chronic obstructive pulmonary disease (COPD) are common chronic respiratory
diseases. Both diseases have incompletely distinct pathophysiology, clinical manifestation …

Inhibitors of phosphodiesterase type 4 (PDE4) act by increasing intracellular concentrations
of cyclic AMP, which has a broad range of anti-inflammatory effects on various key effector …

Phosphodiesterases (PDE) are a family of enzymes responsible for the metabolism of the
intracellular second messengers cyclic AMP and cyclic GMP. PDE4 is a cyclic AMP specific …

Phosphodiesterases hydrolyse intracellular cyclic nucleotides, cyclic adenosine
monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) into inactive 5 …